Table 2.
Summary of Statistics
| Country | n (%) |
| UK | 6 (33.33) |
| USA | 3 (16.67) |
| China | 3 (16.67) |
| Spain | 2 (11.11) |
| Pakistan | 1 (5.56) |
| Belgium | 1 (5.56) |
| Germany | 1 (5.56) |
| Nepal | 1 (5.56) |
| Study Type | n (%) |
| Retrospective Observational | 11 (61.11) |
| Retrospective Cohort | 4 (22.22) |
| Prospective Cohort | 2 (11.11) |
| Descriptive Cross-Sectional | 1 (5.56) |
| Gold Standard | n (%) |
| Blood Culture | 9 (50) |
| Sputum / LRT Culture | 9 (50) |
| Urine Culture | 4 (22.22) |
| Urine Antigen | 4 (22.22) |
| Unspecified Culture | 2 (11.11) |
| Other Markers (no culture) | 7 (38.89) |
| Procalcitonin Cut-Off value | n (%) |
| 2/2.5 ng/mL | 2 (11.11) |
| 1 ng/mL | 2 (11.11) |
| 0.5/0.55 ng/mL | 10 (55.56) |
| 0.3 ng/mL | 1 (5.56) |
| 0.2/0.25 ng/mL | 6 (33.33) |
| 0.1 ng/mL | 2 (11.11) |
| No Cut-Off Values | 3 (16.67) |